A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate canceropen access
- Authors
- Kim, HS[Kim, Hae Su]; Lee, JY[Lee, Ji Yun]; Lee, SJ[Lee, Su Jin]; Lim, HY[Lim, Ho Yeong]; Sung, HH[Sung, Hyun Hwan]; Jeon, HG[Jeon, Hwang Gyun]; Jeong, BC[Jeong, Byong Chang]; Seo, SI[Seo, Seong Il]; Jeon, SS[Jeon, Seong Soo]; Lee, HM[Lee, Hyun Moo]; Choi, HY[Choi, Han-Yong]; Park, SH[Park, Se Hoon]
- Issue Date
- 22-Aug-2017
- Publisher
- BIOMED CENTRAL LTD
- Keywords
- Castrate-resistant prostate cancer; Docetaxel; Biweekly
- Citation
- BMC UROLOGY, v.17
- Indexed
- SCIE
SCOPUS
- Journal Title
- BMC UROLOGY
- Volume
- 17
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/27816
- DOI
- 10.1186/s12894-017-0253-z
- ISSN
- 1471-2490
- Abstract
- Background: The aim of this retrospective study was to evaluate the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with castrate-resistant prostate cancer (CRPC). Methods: We retrospectively reviewed the medical records of 48 patients with metastatic CRPC who were treated with a biweekly regimen (intravenous docetaxel 40 mg/m(2) on day 1 plus prednisolone 5 mg twice daily) between 2012 and 2015 at Samsung Medical Center (Seoul, Korea). Prior to the adoption of a biweekly regimen in Oct 2013, our institutional standard chemotherapy was docetaxel 75 mg/m(2) every 3 weeks for patients with CRPC (n = 24). After Oct 2013, all chemotherapy-naive patients with CRPC received a 40 mg/m(2) biweekly regimen (n = 24). The primary end point was a PSA response, defined as a greater than 50% decline in PSA level from baseline. Results: The baseline characteristics of the patients in the two treatment groups were similar. The most common cause of treatment discontinuation was disease progression, which was exhibited by 17 patients (71%) in the 3-weekly group and 20 (75%) in the biweekly group. PSA responses were observed in 12 (50%) and 11 (46%) patients in the 3-weekly and biweekly groups, respectively (p = 0.683). Time to treatment failure (TTTF, 4.5 vs 3.9 months) and time-to-progression (TTP, 5.0 vs 4.2 months) were not significantly different between the 3-weekly and biweekly groups. Conclusions: Within the limitations of a retrospective study, the biweekly reduced dose docetaxel regimen was active and well-tolerated in Korean patients with metastatic CRPC.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/27816)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.